Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Benitec Biopharma Inc.’s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing genetic medicines, including the BB-301 program for OPMD-related dysphagia. Its reports and current filings cover operating and financial results, clinical-development updates, Regulation FD disclosures, and capital-structure information for its common stock.
The company’s proxy and governance filings describe annual meeting matters, board composition, director compensation, equity incentive arrangements, and related corporate-governance disclosures. Form 8-K filings also record material events such as financial-result releases, operational updates, clinical-study disclosures, and director appointments.
Benitec Biopharma Inc. reported changes to its board of directors. On May 22, 2026, the board appointed David Friedman as a Class III director, with a term running until the company’s 2028 annual meeting of stockholders.
In connection with his appointment, Friedman received options to purchase 35,000 shares of common stock under the 2020 Equity and Incentive Compensation Plan, granted on May 26, 2026 at the Nasdaq closing price and vesting in full before the next annual meeting or on the first anniversary of the grant. On the same date, chief financial officer and secretary Megan Boston resigned from the board as part of an ongoing board composition and governance review, but continues in her executive roles, and her departure from the board was not due to any dispute or disagreement with the company.
Benitec Biopharma Inc. director David Matthew Friedman was granted stock options linked to his board service. The award covers 35,000 options to buy Benitec common stock at an exercise price of $11.45 per share, expiring on May 26, 2036.
The options will vest in full on the earlier of immediately before Benitec’s next annual stockholder meeting or May 26, 2027. According to the disclosure, Friedman is a Managing Director of Suvretta Capital Management, which manages Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. The options are held for the benefit of these funds, and Friedman disclaims beneficial ownership, while the funds and Suvretta Capital may be deemed to have an indirect pecuniary interest in the award.
Benitec Biopharma Inc. filed an initial ownership report for director David Matthew Friedman. This Form 3 shows his status as a director but does not list any shareholdings or recent transactions. It serves as a baseline disclosure of his insider position with the company.
Benitec Biopharma Inc. reports results for the quarter and nine months ended March 31, 2026, as it advances its BB-301 genetic medicine for Oculopharyngeal Muscular Dystrophy (OPMD). The company generated no revenue and recorded a nine‑month net loss of $32.7 million.
Operating expenses reached $36.8 million for the nine months, driven by $15.5 million in research and development and $21.3 million in general and administrative costs, including higher share‑based compensation. Other income of $4.0 million, mainly from interest on cash, partially offset these losses.
Benitec strengthened its balance sheet, ending March 31, 2026 with $184.8 million in cash, cash equivalents and restricted cash, up from $97.9 million at June 30, 2025, after raising about $104.5 million in gross proceeds from common stock offerings and warrant exercises. Management states this cash should fund operations for at least twelve months while BB-301 progresses through its Phase 1b/2a program.
Benitec Biopharma reported third quarter 2026 results and highlighted continued progress for its lead gene therapy BB-301 for Oculopharyngeal Muscular Dystrophy. Total expenses for the quarter ended March 31, 2026 were $13.6 million, down from $15.3 million a year earlier, reflecting lower general and administrative costs. The company recorded a net loss of $11.9 million, or $0.24 per share, compared with a loss of $14.5 million, or $0.38 per share, in the prior-year quarter.
Benitec ended March 31, 2026 with $184.8 million in cash and cash equivalents and states it is well-capitalized to advance BB-301 through completion of a pivotal study. Phase 1b/2a interim data show durable, disease-modifying responses at low and high doses, with all Cohort 1 patients completing 12-month follow-up and no treatment-related severe adverse events reported. The company plans to meet the FDA mid-year to formalize the pivotal BB-301 study design and expects updated interim clinical results for Cohorts 1 and 2 in the second half of 2026.
Benitec Biopharma Inc. filed an amended annual report mainly to include the conformed signature of its independent auditor, updated exhibit references, and fresh CEO/CFO certifications, without changing the substantive disclosures from the original Form 10‑K.
For the year ended June 30, 2025, Benitec reported a net loss of $37.9 million versus $21.8 million a year earlier, driven by higher operating expenses of $41.8 million, including $18.3 million in research and development and $23.4 million in general and administrative costs. Share‑based compensation rose to $17.4 million. Cash, cash equivalents, and restricted cash increased to $97.9 million, supported by equity financings and warrant exercises providing $70.5 million of net proceeds in fiscal 2025 and an April 2024 PIPE that raised $40.0 million of gross proceeds. Stockholders’ equity grew to $97.3 million, with 26,250,469 common shares outstanding at June 30, 2025, and management believes existing cash will fund operations for at least the next twelve months.
Benitec Biopharma reported its second fiscal quarter ended December 31, 2025, highlighting both financial results and progress for BB-301, its gene therapy for Oculopharyngeal Muscular Dystrophy-related dysphagia. Total expenses were $13.4 million, up from $10.8 million a year earlier, driven mainly by higher general and administrative costs. Net loss attributable to shareholders was $11.8 million, or $(0.26) per share, compared with a net loss of $9.6 million, also $(0.26) per share, in the prior-year quarter. The company held $189 million in cash and cash equivalents as of December 31, 2025, providing substantial funding for its clinical programs.
Clinically, all four patients in Cohort 1 of the BB-301 Phase 1b/2a study were classified as responders at 12 months using a predefined Responder Analysis, indicating durable benefit. One patient maintained and deepened improvements in swallowing measures and symptom burden at 24 months post-treatment. Enrollment in Cohort 2 at a higher BB-301 dose is ongoing, with an interim update planned for mid-2026. BB-301 has Orphan Drug and Fast Track designations, and the company plans an FDA meeting in mid-2026 to confirm the pivotal study design.
Benitec Biopharma Inc. reported another quarter as a clinical-stage biotech with no product revenue and continued investment in its genetic medicine platform. For the six months ended December 31, 2025, the company recorded a net loss of $20.8 million, compared with $14.6 million a year earlier, driven by higher research and development spending of $9.2 million and general and administrative expenses of $14.0 million.
Benitec significantly strengthened its balance sheet, ending the period with $188.8 million in cash and cash equivalents, up from $97.7 million at June 30, 2025, primarily from equity offerings that generated gross proceeds of about $104.5 million. Total assets were $190.7 million and stockholders’ equity was $187.4 million. Management states this cash should fund operations for at least the next twelve months as the company advances its lead OPMD gene therapy candidate BB-301 through an ongoing Phase 1b/2a program. Shares outstanding were 34,254,907 at December 31, 2025 and 34,354,334 as of February 6, 2026.
Benitec Biopharma Inc. is registering 1,481,481 shares of common stock for resale by entities affiliated with Suvretta Capital that bought these shares in a November 2025 registered direct offering. Benitec will not receive any proceeds from these secondary sales but will cover registration expenses.
The resale follows concurrent November 2025 offerings in which Benitec sold 5,930,000 shares in an underwritten deal and 1,481,481 shares in the registered direct deal at $13.50 per share, plus an additional 328,889 shares later, for aggregate gross proceeds of about $100 million. The company is a clinical-stage biotech developing BB-301, a “silence and replace” gene therapy candidate for Oculopharyngeal Muscular Dystrophy, using its DNA-directed RNA interference platform.
Entities affiliated with Suvretta Capital beneficially owned 17,952,309 shares of common stock as of February 10, 2026 and, assuming full resale of the registered shares, would beneficially own 16,470,828 shares, representing 40.9% of Benitec’s common stock.
Benitec Biopharma Inc. has filed a resale registration statement covering 1,481,481 shares of common stock held by existing investors from a prior registered direct offering. The company is registering these shares to satisfy a Registration Rights Agreement tied to a November 7, 2025 financing.
Benitec will not receive any proceeds from sales under this prospectus, though it will cover registration expenses. The shares are owned by entities affiliated with Suvretta Capital Management, which beneficially held 17,952,309 shares as of January 26, 2026, representing a significant ownership stake. The filing highlights risks from concentrated ownership, potential warrant exercises, and resale-related stock price pressure.